What happened
ABL Bio reported consolidated results for FY2025: revenue of US$54M (+137.6% year on year), an operating loss of US$27.5M and a net loss of US$25.8M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$54M |
|---|---|
| Revenue vs a year earlier | +137.6% |
| Operating profit | −US$27.5M |
| Net income | −US$25.8M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-06, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260206902001 → open original filing |
Source: DART. Information only, not investment advice.